News Conference News ACC 2026 Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering Michael O'Riordan April 01, 2026
News Conference News ACC 2026 PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Michael O'Riordan March 29, 2026
News Daily News Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1 Caitlin E. Cox March 19, 2026
News Daily News Ultraprocessed Food Again Linked to Higher CVD Risk: MESA Michael O'Riordan March 17, 2026
News Daily News Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines Michael O'Riordan March 13, 2026
News Daily News Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone Michael O'Riordan March 03, 2026
News Daily News Side Effects of Statins Might Be Overstated: CTT Collaboration Michael O'Riordan February 12, 2026
News Daily News Both Low-fat and Low-carb Diets Tied to Less Heart Disease Michael O'Riordan February 11, 2026
News Daily News Weight Regained Within 18 Months of Stopping GLP-1 Drugs Michael O'Riordan January 08, 2026
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Daily News Risk Calculators Miss Many Patients Who Present With First MI Michael O'Riordan November 21, 2025
News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids Michael O'Riordan November 10, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News High Aerobic Fitness Linked to Less Chronic Disease in Later Life Michael O'Riordan October 10, 2025
News Daily News Risk Factors Present in Nearly All Patients Who Develop CVD Michael O'Riordan October 02, 2025